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Objective. To analyze clinico-pathological features of Chinese patients with UPSC, and investigate roles of Her-2/neu protein
expressionandgeneampliﬁcationinUPSCprognosis.Methods.Thirty-sixpatientswithUPSCtreatedinCancerHospitalofFudan
Universityfrom1996to2006wereanalysedretrospectively.Chromogenicinsituhybridization(CISH)andimmunohistochemistry
(IHC) were performed to evaluate Her-2/neu gene ampliﬁcation and protein expression respectively. Results. The median age was
63years,and61%(22/36)werelatestages(stageIII/IV).The1-year,3-year,and5-yearoverallsurvival(OS)was73.1%,51.9%and
43.9%, respectively. Advanced stages (P = .0006) and deep myometrial invasion (P = .0138) were signiﬁcantly associtated with a
shorter OS. In 36 cases, 27.8% (10/36) showed 2+ staining and 8.3% (3/36) showed 3+ by IHC. Ampliﬁcation of the Her-2/neu
gene was observed in 11.1% (4/36) cases. The 5-year overall survival rate in Her-2/neu IHC 2+ ∼ 3+ and 0 ∼ 1+ cases was 12.9%
and 68.6% respectively. Her-2/neu protein expression 2+ ∼ 3+ was signiﬁcantly associated with advanced surgical stage and worse
overall survival (P = .03 and P = .0023, resp.). Conclusion. Chinesepatients with UPSC showed characteristics of deep myometrial
invasion, advanced stages and poor overall survival. Her-2/neu protein overexpression is associated with advanced stage and poor
survival outcome.
1.Introduction
Endometrial cancer is the fourth most common cancer
among women in the United States. According to the latest
data from the National Cancer Institute, approximately
40,100 new cases and 7,470 deaths from uterine cancer
are expected in 2008 [1]. In Shanghai, China, the age-
adjusted incidence of endometrial cancer increased by 4.41%
per year between 1973 to 1975 and 1997 to 1999 [2–4].
Endometrialcancerhasbeendividedintotwosubtypes(type
I and II) based on diﬀerent morphological appearance and
clinicalpathological characteristics [5–7]. Type I, which is
endometrioid histology with relatively low-grade features
and good prognoses, occurs most often in postmenopausal
women and is associated with unopposed estrogen exposure.
In contrast, type II endometrial cancer comprises of nonen-
dometrial histology with an aggressive clinical course and
poor prognoses.
Uterine papillary serous carcinoma (UPSC) is the most
common subtype of type II endometrial cancer. It was
ﬁrst described by Hendrickson et al. [8] in 1982, and
histologically similar to high-grade ovarian cancer. The
microscopic criteria for diagnosis were described as neoplas-
tic epithelium, characterized by serous diﬀerentiation with
psammoma bodies present and predominantly papillary
architecture [8]. Although UPSC represents only about
10% of endometrial cancers, they account for over 50% of
recurrences and deaths caused by endometrial cancer. The 5-
year overall survival (OS) for women with UPSC is only 46%
for all stages [9]. Comprehensive surgical staging is recom-
mendedforallpatientswithUPSC,regardlessofthedepthof
myometrial invasion of the tumor [9, 10]. Chemotherapy is
recommended after the surgery, but unlike ovarian papillary
serous carcinomas, UPSC is a chemoresistant disease from
onset, with low response rates and a short duration of
response [11, 12]. Given the overall poor prognosis of these2 ISRN Obstetrics and Gynecology
patients, new treatment modalities are urgently needed for
UPSC.
Her-2/neu is one of the most studied molecular markers
in anticancer therapy. Her-2/neu, also known as c-erbB2,
is a member of the epidermal growth factor receptor
transmembrane receptor tyrosine kinase family [13]. 25%
to 30% of breast cancers were found to have Her-2/neu
overexpression, which is considered as a negative prognostic
factor [14, 15]a sw e l la sap r e d i c t i v em a r k e ro fr e s i s t a n c et o
tamoxifen therapy, beneﬁt from doxorubicin-based adjuvant
chemotherapy, and trastuzumab (anti-Her-2 monoclonal
antibody) [16–18]. Recently, a striking overexpression of
the Her-2/neu in UPSC has been identiﬁed by Santin et al,
with the rates ranging from 18% to 80% in diﬀerent studies
[19–21]. In this study, we conducted a single institutional
review of 10 years summary of this rare disease, which,
to our knowledge, is the largest one so far analysing the
clinicopathological features, prognostic factors, and Her-
2/neu status of Chinese patients with UPSC. The purpose of
this study is to better understand clinicopathological features
of UPSC and the relationship with Her-2/neu abnormality.
2.MaterialsandMethods
2.1. Patient Population and Tumor Specimens. All the slides
of the patients with endometrial carcinoma who underwent
surgery at Cancer hospital, Fudan University, from January
1996 to January 2006, were reviewed by two pathologists
separately. If there was dispute in diagnosis between them,
slides would be reviewed by another pathologist who made
the ﬁnal diagnosis. Altogether 457 patients with endometrial
cancer were treated in our hospital during the last 10 years
and 36 cases of UPSC were rediagnosed, which accounted
for about 8%. Their clinical and surgical pathology reports
were recorded. Patients were staged according to the 1988
FIGO surgical criteria [22]. Overall Survival (OS) was the
primary end-point evaluated. It was calculated from the date
of the surgical diagnosis. The information on survival was
obtained in the medical record and death certiﬁcate. If this
information was not available, the patient was censored after
her last contact.
2.2. Immunohistochemistry (IHC). Formalin-ﬁxed, paraﬃn-
embedded specimens were collected from tissue bank of
Cancer hospital, Fudan University. For all cases, a routine
hematoxylin and eosin slide was evaluated to ensure that
the specimen evaluated had serous carcinoma. IHC was
performed using c-erbB-2/Her-2/neu Ab (A0485, Dako
Corp., Denmark). This antibody is a polyclonal rabbit anti-
human c-erbB-2 oncoprotein. IHC staining was performed
on 4-um-thick paraﬃn-embedded sections according to
the manufacturer’s instructions. Brieﬂy, after pretreatment
with 10mM citrate buﬀer at pH 6.0 using a steamer, they
were incubated with c-erbB-2/Her-2/neu Ab at 37◦Cf o r2
hours, then incubated with immunoperoxidase anti-rabbit
Ab (K4003, Dako Corp., Denmark) for half an hour and
followed by substrate-chromogen solution( DAB). Negative
controls were analyzed on slides incubated without the
antibodies. Her-2/neu-expressing breast cancer was used as
a positive control. The intensity of immunostaining was
graded as follows: negative (0); incomplete membranous
staining or complete membranous staining in less than
10% of the tumor cells (1+); moderate intensity, complete
membranous staining in greater than 10% of the tumor cells
(2+); or strong intensity, complete membranous staining in
greater than 10% of the tumor cells (3+). Tumors with 2+
or 3+ staining were considered Her-2/neu overexpression
[23, 24]. The sections were examined by light microscopy by
two diﬀerent pathologists without knowledge of the clinical
outcome.
2.3. Chromogenic In Situ Hybridization (CISH). CISH was
done using Zymed SPoT-Light HER-2 CISH Kit (84-0146)
according to instructions of manufacture. Sections of 3μm
were cut from paraﬃn-embedded archival tissue from tissue
b a n k .T h es e c t i o n sw e r ed e p a r a ﬃnized and pretreated in
a microwave oven at 100◦C for 15 minutes. After a brief
rinsing with Tris-buﬀered saline (0.05mol/L Tris/HCl saline,
pH 7.4–7.6), the slides were digested with Enzyme for
5 to 10 minutes (the time for each slide was diﬀerent),
followed by rinsing with distilled water for 3 times, and
dehydrating with graded ethanols. The digoxigenin-labelled
Her-2/neu probe (Zymed) was applied onto the slides,
covered with coverslips and denatured at 95◦Cf o r5m i n u t e s .
The hybridization was performed overnight at 37◦C. The
slides were then washed with standard saline citrate (SSC)
in room temperature brieﬂy then with SSC at 75◦Cf o r5
minutes. Immunodetection was performed by the labelled
avidin-biotin complex peroxidase system according to the
manufacturer’s instructions. Finally, sections were lightly
counterstainedwithhaematoxylin.Breastcancerwithknown
Her-2/neu-ampliﬁcation was used as a positive control.
Benign endometrium was used as a negative control. Her-
2/neu gene signals were scored in histological sections, in at
least 150 neoplastic cells, using a conventional microscope
(Olympus). Tumours were classiﬁed, depending on the
number of gene copies in the nuclei, as normal (1–5 copies)
and ampliﬁed (>6 copies or when large gene copy clusters
were seen in at least 50%). In addition, ampliﬁed tumours
were classiﬁed as low-level (6–10 copies) or high level (>10
copies).
2.4. Statistical Analysis. X2 tests were performed to assess
prognostic factors. Kaplan-Meier survival curves were used
to estimate OS. The log-rank test was used to compare
survival curves. Cox’s proportional hazards regression was
used to model survival with Her-2/neu IHC overexpression
and clinicopathological variables typically associated with
prognosis. Spearman correlation was used to analyze the
relation between the results of IHC and CISH. SPSS version
11.5 software was used for all analyses.
3. Results
3.1. Clinicopathological Features of Patients. The median
age of the patients was 63 years (mean 64 years, rangeISRN Obstetrics and Gynecology 3
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Figure 1: (a) Hematoxylin and eosin stain and (b) immunohistochemical staining 3+ for Her-2/neu expression on paraﬃn-embedded
uterine serous carcinoma specimens. ×200. (c) Her-2/neu gene ampliﬁcation ampliﬁed in high level. ×400.
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Figure 2: Overall survival curve for all 36 patients with UPSC.
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Figure 3: Kaplan-Meier curve based on Her-2/neu protein expres-
sion (IHC positive versus IHC negative, P = .0023).4 ISRN Obstetrics and Gynecology
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Figure 4: Kaplan-Meier curve based on stage (stage I/IIversus stage
III/IV, P = .003).
45∼81 years). The median BWI (Body Weight Index)
was 23.8kg/m2 (mean 23.73, range 17.6∼33.8). The main
presenting symptoms were abnormal vaginal bleeding (86%,
31/36), while other 4 patients ﬁrst presented with abdominal
symptoms such as abdominal mass and ascites, and 1 with
vaginal discharge.16patients(45.7%)werecomplicatedwith
hypertension and 4 patients (11.4%) with diabetes. 8 cases
or relatives had history of other cancers, including 1 with
ovarian mucous adenocarcinoma, 2 with breast cancer, 1
with endometrial cancer, 3 with gastrointestinal cancer,a n d
1w i t hthyroid neoplasms.
Of these 36 patients, 11 (31%) were stage I (1 IA, 6 IB,
4 IC), 3 (8%) were stage II (1 IIA, 2 IIB), 9 (25%) were
stage III (4 IIIA, 1 IIIB, 4 IIIC), and 13 (36%) were stage
IV (13 IVB). Altogether 39% were early stages (stage I/II)
and 61% were late stages (stage III/IV). 21 tumors invaded
more than half of myometrium, in which 11 invaded to
serosa of the uterus. 15 tumors invaded less than half of
myometrium. And only two patients had no myometrial
invasion. 20 tumors (55.6%) demonstrated LVSI (Lymph-
vascular space invasion). Twenty-seven tumors (75%) had
overexpression of p53, while positive ER expression was only
detected in 10 cases (27.8%), and PR expression in 7 cases
(19.4%).
All patients underwent exploratory surgery, hysterec-
tomy, bilateral salpingo-oophorectomy, omentectomy, pelvic
lymphadenectomy, and/or para-aortic lymphadenectomy.
Patients with stage IVB disease also received cytoreductive
surgery.4 patients received chemotherapy beforethe surgery.
After the surgery, 14 patients received platinum-based
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Figure 5: Kaplan-Meier curve based on myometrial invasion (≥1/2
versus <1/2, P = .0138).
chemotherapy including cisplatin, cyclophosphamide and
anthracycline, or carboplatin and paclitaxel, and so forth. 4
patients received whole pelvic radiotherapy with 2 extended
to the para-aortic ﬁeld. 4 patients received whole pelvic
radiotherapy combined with platinum-based chemotherapy.
6 patients had oral tamoxifen or progestin, and 8 patients
were observed after the surgery.
3.2. IHC and CISH. Of the 36 cases, 13 (36.1%) patients
had Her-2/neu protein overexpression by IHC. In this 13
patients, 10 (27.8%) showed 2+ and 3 (8.3%) showed 3+.
(Figure 1). The remaining 11 samples showed 1+ and 12
showed 0 for Her-2/neu protein. The clinicopathological
features by Her-2/neu IHC status were summarized in
Table 1. Overexpression of Her-2/neu was seen in 50.0%
(11/22) of UPSC patients with advanced disease (Stage III∼
IV), compared to 14.3% (2/14) of patients with early disease
(Stage I∼II). Patients with overexpression of Her-2/neu were
signiﬁcantlymorelikelytohaveadvanced-stagediseasewhen
compared to Her-2/neu negative patients (OR = 6.0, 95%CI:
1.08–33.32, P = .03).
CISH was performed in all UPSC cases. Four out of
the 36 (11.1%) cases were found with Her-2/neu gene
ampliﬁcation, in which 3 ampliﬁed in high level and 1 in
low level (Figure 1). The correlation between IHC and CISH
results were assessed (Table 2). All IHC 3+ (100%, 3/3) cases
had Her-2/neu gene ampliﬁcation. And all IHC negative
cases had normal Her-2/neu gene copies (1–5 copies).
Therefore, complete concordance between IHC and CISH
was observed in IHC 3+ and negative cases (P = .001,ISRN Obstetrics and Gynecology 5
Table 1: Clinicopathological features by Her-2/neu IHC status.
Clinicopathological features by Her-2 IHC status
positive (n = 13) negative (n = 23) P value
Age (years)
Median (range) 64 (58–77) 61 (45–81) .22
Stage .03
I∼II 2 (15.4%) 12 (52.2%)
III∼IV 11 (84.6%) 11 (47.8%)
Myometrial invasion .78
<1/2 5 (38.5%) 10 (43.5%)
1/2 8 (61.5%) 13 (56.5%)
Histology .33
Pure 9 (69.2%) 12 (52.2%)
Mixed 4 (30.8%) 11 (47.8%)
LVSI .4
Absent 7 (53.8%) 9 (39.1%)
Present 6 (46.2%) 14 (60.9%)
Grade .45
II 3 (23.1%) 3 (13.0%)
III 10 (76.9%) 20 (87.0%)
p53 .08
Absent 1 (7.7%) 8 (34.8%)
Present 12 (92.3%) 15 (65.2%)
ER .69
Absent 10 (76.9%) 16 (69.6%)
Present 3 (23.1%) 7 (30.4%)
PR .66
Absent 11 (84.6%) 18 (78.3%)
Present 2 (15.4%) 5 (21.7%)
Spearman Correlation). Only one out of 10 cases scored as
2+ by IHC (10%, 1/10) was found with gene ampliﬁcation
by CISH.
3.3. Survival Analyses. The median follow-up time for all
of the patients was 31 months (range, < 1 to 115 months).
During the follow-up time, 17 patients died (47.2%), and 15
ofthesedeathswererelatedtothisdisease.Ninepatientswere
observed to have disease progression during followup, with
4i np e l v i s ,2i nl i v e r ,1i nb r a i n ,1i nb o t hl i v e ra n dp e l v i s ,
and 1 in both liver and brain. The 1-year, 3-year, and 5-year
overallsurvivalforallpatientswas73.1%,51.9%,and43.9%,
respectively (Figure 2,).
The results of univariate survival analysis of Her-2/neu
protein expression and other clinicopathological factors are
shown in Table 3. The 5-year overall survival rate for Her-
2/neu IHC positive and negative cases was 12.9% and 68.6%,
respectively. Poorer outcome (Kaplan–Meier) was observed
for patients with Her-2/neu overexpression positive than
negative patients (P = .0023) (Figure 3). The 5-year overall
survival rate for early and advanced stage cases was 60.4%
and 16%, respectively. Advanced stages (P = .0006) and
deep myometrial invasion (P = .0138) were also signiﬁcantly
associtated with a shorter OS (Figures 4 and 5).
4. Discussion
UPSC is a rare type of endometrial cancer, whose clini-
c a lf e a t u r e sa r ed i ﬀerent from endometrioid endometrial
adenocarcinoma. The median age of UPSC was 64 years
in this study, similar to previous report, but older than
the median age of women with endometrioid endometrial
cancers in China [25]. Unlike endometrioid endometrial
cancers, UPSC was not associated with obesity. The median
BWI was 23.8kg/m2 in this study. And most important of
all, compared to patients with endometrioid endometrial
adenocarcinomas, patients with UPSC tend to have deep
myometrial invasion, high-stage diseases, and worse overall
survival, as we had discussed previously in [25]. In our study,
61% were late stages. More than half of patients (58.3%)
haddeepmyometrialinvasion.The1-year,3-year,and5-year
overall survival was 73.1%, 51.9%, and 43.9%, respectively.
Although racial diﬀerences in the uterine cancer have
been previously published, most of these studies have
focused on disparities between African Americans and
whites. Santin et al. noted that black patients with UPSC
tended to be younger, had higher Her-2/neu expression and
short survival than white [26]. Slomovitz [9] summarized
the clinical features of 129 cases with UPSC. In his study,
93% patients were Caucasian, and only 2% were Asian.6 ISRN Obstetrics and Gynecology
Table 2: Correlation of Her-2/neu status by IHC and CISH.
Her-2 protein expression by IHC P value
3+( n = 3) 2+ (n = 10) 1+ (n = 11) 0 (n = 12)
Her-2 Ampliﬁcation by CISH
High-level 2 1 0 0
.001 Low-level 1 0 0 0
No 0 9 11 12
Table 3: Univariate analysis of Her-2/neu IHC status and clinicopathological factors with overall survival.
No. of patients No. of Deaths Survival Rate (%) P value
1-year 3-years 5-years
36 17 73.1 51.9 43.9
Her-2/neu by IHC .0023
Positive 13 11 60 25.7 12.9
Negative 23 6 81 68.6 68.6
Stage .0006
I∼II 14 3 92.6 84.5 60.4
III∼IV 22 14 60 26.7 16
Myometrial invasion .0138
<1/2 15 4 85.7 77.6 55.4
1/2 21 13 64.1 33.1 19.9
Histology .948
Pure 21 10 74.4 50.6 30.3
Mixed 15 7 71.4 54 36
LVSI .4884
Present 20 10 63.2 51.1 30.7
Absent 16 7 86.2 52.8 37.7
Grade .8689
II 6 3 75 50 50
III 30 14 68.4 51.8 41.5
Therefore, little is known about Asian patients with UPSC
till now. Recent study had reported the racial disparities
betweenAsians andwhites.Zhang et al.[27] compared2,144
Asians and 32,999 whites with corpus cancer in the United
States,andfoundthatAsianspresentedatayoungerage,with
more advanced stage disease and higher 5-year survival rates
than whites. In our study, similar to whites, main presenting
symptoms were abnormal vaginal bleeding and with median
BWI of 23.8kg/m2, patients with UPSC ware not associated
with obesity. On the other hand, Asian patients with UPSC
had younger age (64 years) and more late stage diseases
(61%) than whites compared to the previous report [9], in
which median age was 68 years for whites and 56% patients
were in late stages. The 3-year and 5-year overall survival
in our study was 51.9% and 43.9%, respectively, which was
a little worse than whites, whose 3-year and 5-year overall
survival was 62.6% and 45.9%, respectively [9].
Recently, Her-2/neu overexpression was found to be a
common event in UPSC. Grushko et al. [28] found that
UPSC had more Her-2/neu overexpression than all other
types of endometrial cancers (23 of 38, 61% versus 81 of
196, 41%, resp., P = .03). Santin et al. [20, 21]r e p o r t e d
that 62% ∼80% of UPSC overexpressed Her-2/neu protein,
and others reported overexpression rates varyng from 40%
to 48% [29–31]. In contrast, Slomovitz et al. [19]r e p o r t e d
overexpression of Her-2/neu in only 18% (12 of 68) of UPSC
patients. Table 4 summmariued the results and methods of
the studies on Her-2/neu status in UPSC. In our study, we
demonstratedthat 36% ofpatients with UPSCoverexpressed
Her-2/neu protein. The diﬀerences of the rate of Her-2/neu
overexpression, might be due to diﬀerent antibody, inherent
intraobserver variability, and most important of all, racial
disparity.
In our study, patients with Her-2/neu overexpression
were signiﬁcantly more likely to have advanced stage disease
when compared to Her-2/neu negative patients (P = .03).
Overexpression of Her-2/neu was seen in 50.0% (11/22) of
UPSC patients with advanced disease, compared to 14.3%
(2/14) of patients with early disease. Similar ﬁndings were
reported by Slomovitz, Santin, and D´ ıaz-Montes et al., in
whichoverexpressionofHer-2/neuinpatientswithadvanced
disease were 24% ∼81.8%, compared to 8% ∼28.6% of
patients with early disease [19, 20, 30]. D´ ıaz-Montes et al.
also demonstrated that overexpression of Her-2/neu was
associated with higher Ki-67 index, larger tumor sizes, and
w o r s es u r v i v a lo u t c o m e .ISRN Obstetrics and Gynecology 7
Table 4: Summary of related articles on Her-2/neu status in UPSC.
Year Author Methods Number of Patients Positivity (%)
1994 Prat et al. IHC 10 40% (4/10)
2001 Halperin et al. IHC 22 45% (10/22)
2002 Santin et al. IHC 10 80% (8/10)
2004 Slomovitiz et al. IHC 68 18% (12/68)
FISH 12 17% (2/12)
2005 Santin et al. IHC 26 62% (16/26)
FISH 42% (11/26)
2006 Diaz-Montes IHC 25 48% (12/25)
2008 Grushko et al. IHC 38 61% (23/38)
FISH 28 21% (6/28)
Insurvivalanalysis,wefoundthattheoverallsurvivalwas
worse for patients with Her-2/neu protein positive tumors
thanHer-2/neunegativeones(P = .0023).The5-yearoverall
survival for Her-2/neu IHC positive and negative cases was
12.9% and 68.6%, respectively. Slomovitz et al. [19] also
revealedthatthe5-yearoverallsurvivalinUPSCpatientswas
0%inHer-2/neuIHCpositivecasesversus45%inHer-2/neu
negative ones (P = .008). And Santin et al. [26]d e m o n -
strated that short survival was associated signiﬁcantly with
Her-2/neu overexpression compared with IHC expression
0∼1+(P = .002). All of these ﬁndings suggested that Her-
2/neu overexpression was a useful prognostic factor for this
aggressive subtype of endometrial cancer. Besides Her-2/neu
IHC overexpression, we also found that deep myometrial
invasion (P = .0138) and late stages (P = .003) were
associtated with a shorter OS.
WeusedCISHtodetecttheHer-2/neugeneampliﬁcation
in our study and found Her-2/neu gene ampliﬁcation in four
cases(11.1%). Santin etal.[32] revealedthat Her-2/neu gene
ampliﬁcation was correlated with a poor survival outcome in
patients with UPSC (P = .0084). Because of the small size
of Her-2/neu ampliﬁcation in our study, we did not ﬁnd the
eﬀect of Her-2/neu ampliﬁcation on overall survival.
Her-2/neu gene ampliﬁcation was found in all IHC 3+
cases (100%, 3/3). But in IHC 2+ cases, only one out of
ten cases had Her-2/neu gene ampliﬁcation. As we know,
patients who have Her-2/neu gene ampliﬁcation respond
bettertotrastuzumab.Therefore,like breastcancer,theentry
criteria of trastuzumab in UPSC should be conﬁned to
IHC 3+ cases, excluding the 2+ cases unless it is proved
to have Her-2/neu ampliﬁcation by CISH or FISH. The
Gynecologic Oncology Group conducted a phase II study
usingtrastuzumabasasingleagentinpatientswithadvanced
stage or recurrent endometrial cancer with Her-2/neu IHC
2+ or 3+ staining, but found no activity of trastuzumab
in heavily pretreated patients. 13% of cases demonstrated
gene ampliﬁcation and 37% demonstrated moderate or high
immunostaining. Entry criteria were then revised to include
onlythosepatientswhosetumorswereFISHpositive,butthe
study was ﬁnally closed due to slow enrollment [33].
Santin et al. [21] studied the eﬀects of trastuzumab
in UPSC cell lines and found that UPSC cell lines were
highly sensitive to Herceptin mediated antibody-dependent
cellular cytotoxicity (ADCC) and cell proliferation was
inhibited. Villella et al. [34] tried to use trastuzumab
therapy (4mg/kg intravenously over 90min, then mainte-
nance dose of 2mg/kg intravenously over 30min weekly
until progression of disease) in patients with UPSC who
expressed Her-2/neu 3+ by IHC. Two patients with 3+
overexpression received trastuzumab treatment. One patient
with IVB disease had complete response and the other with
IIIC disease had stable disease for 3 months. Targeting Her-
2/neu might be beneﬁcial for a select group of patients with
UPSC.
In conclusion, our data revealed that Chinese patients
with UPSC had characteristics of deep myometrial inva-
sion, advanced stages and poor overall survival. Her-2/neu
overexpression, rather than Her/neu gene ampliﬁcation, is
associated with advanced stage and poor survival outcome.
Her-2/neu might be a therapeutic target in refractory UPSC
patients, but it should be further evaluated by randomized
clinical trials.
References
[1] A.Jemal,R.Siegel,E.Wardetal.,“Cancerstatistics,2008,”CA:
Cancer Journal for Clinicians, vol. 58, no. 2, pp. 71–96, 2008.
[ 2 ]F .J i n ,X . - O .S h u ,S .S .D e v e s a ,W .Z h e n g ,W .J .B l o t ,a n dY . -
T. Gao, “Incidence trends for cancers of the breast, ovary, and
corpus uteri in urban Shanghai, 1972–1989,” Cancer Causes
and Control, vol. 4, no. 4, pp. 355–360, 1993.
[3] F. Jin, S. S. Devesa, W.-H. Chow et al., “Cancer incidence
trends in urban Shanghai, 1972–1994: an update,” Interna-
tional Journal of Cancer, vol. 83, no. 4, pp. 435–440, 1999.
[4] W. Zhang, Y. B. Xiang, Z. W. Liu et al., “Cancer incidence
trend among elderly people in urban Shanghai in 1973–1999,”
Chinese Journal of Geriatrics, vol. 24, pp. 701–704, 2005.
[5] J. V. Bokhman, “Two pathogenetic types of endometrial
carcinoma,” Gynecologic Oncology, vol. 15, no. 1, pp. 10–17,
1983.
[ 6 ] F .A m a n t ,P .M o e rm a n ,P .N ev e n ,D .T i m m e rm a n ,E .V a nL i m -
bergen, and I. Vergote, “Endometrial cancer,” The Lancet, vol.
366, no. 9484, pp. 491–505, 2005.
[7] J. L. Hecht and G. L. Mutter, “Molecular and pathologic
aspects of endometrial carcinogenesis,” Journal of Clinical
Oncology, vol. 24, no. 29, pp. 4783–4791, 2006.8 ISRN Obstetrics and Gynecology
[ 8 ]M .H e n d r i c k s o n ,J .R o s s ,P .E i f e l ,A .M a r t i n e z ,a n dR .K e m p -
son, “Uterine papillary serous carcinoma. A highly malignant
form of endometrial adenocarcinoma,” American Journal of
Surgical Pathology, vol. 6, no. 2, pp. 93–108, 1982.
[ 9 ]B .M .S l o m o v i t z ,T .W .B u r k e ,P .J .E i f e le ta l . ,“ U t e r i n e
papillaryserouscarcinoma(UPSC):asingleinstitutionreview
of129cases,”GynecologicOncology,vol.91,no.3,pp.463–469,
2003.
[10] J. K. Chan, V. Loizzi, M. Youssef et al., “Signiﬁcance of
comprehensivesurgicalstaginginnoninvasivepapillaryserous
carcinoma of the endometrium,” Gynecologic Oncology, vol.
90, no. 1, pp. 181–185, 2003.
[11] L. Ramondetta, T. W. Burke, C. Levenback, M. Bevers, D.
Bodurka-Bevers, and D. M. Gershenson, “Treatment of uter-
ine papillary serous carcinoma with paclitaxel,” Gynecologic
Oncology, vol. 82, no. 1, pp. 156–161, 2001.
[12] K. M. Zanotti, J. L. Belinson, A. W. Kennedy, K. D. Webster,
and M. Markman, “The use of paclitaxel and platinum-
based chemotherapy in uterine papillary serous carcinoma,”
Gynecologic Oncology, vol. 74, no. 2, pp. 272–277, 1999.
[13] P. Casalini, M. V. Iorio, E. Galmozzi, and S. M´ enard, “Role
of HER receptors family in development and diﬀerentiation,”
Journal of Cellular Physiology, vol. 200, no. 3, pp. 343–350,
2004.
[14] D. J. Slamon, G. M. Clark, and S. G. Wong, “Human breast
cancer: correlation of relapse and survival with ampliﬁcation
of the HER-2/neu oncogene,” Science, vol. 235, no. 4785, pp.
177–182, 1987.
[15] M. F. Press, L. Bernstein, P. A. Thomas et al., “HER-
2/neu gene ampliﬁcation characterized by ﬂuorescence in
situ hybridization: poor prognosis in node-negative breast
carcinomas,” Journal of Clinical Oncology, vol. 15, no. 8, pp.
2894–2904, 1997.
[16] M. J. Ellis, A. Coop, B. Singh et al., “Letrozole is more eﬀective
neoadjuvant endocrine therapy than tamoxifen for ErbB-1-
and/or ErbB-2-positive, estrogen receptor-positive primary
breast cancer: evidence from a phase III randomized trial,”
Journal of Clinical Oncology, vol. 19, no. 18, pp. 3808–3816,
2001.
[17] S. Paik, J. Bryant, C. Park et al., “erbB-2 and response to
doxorubicin in patients with axillary lymph node-positive,
hormone receptor-negative breast cancer,” Journal of the
National Cancer Institute, vol. 90, no. 18, pp. 1361–1370, 1998.
[18] E. H. Romond, E. A. Perez, J. Bryant et al., “Trastuzumab plus
adjuvant chemotherapy for operable HER2-positive breast
cancer,” The New England Journal of Medicine, vol. 353, no. 16,
pp. 1673–1684, 2005.
[19] B. M. Slomovitz, R. R. Broaddus, T. W. Burke et al., “Her-
2/neu overexpression and ampliﬁcation in uterine papillary
serous carcinoma,” Journal of Clinical Oncology, vol. 22, no.
15, pp. 3126–3132, 2004.
[20] A. D. Santin, S. Bellone, S. Van Stedum et al., “Determination
of HER2/neu status in uterine serous papillary carcinoma:
comparative analysis of immunohistochemistry and ﬂuores-
cence in situ hybridization,” Gynecologic Oncology, vol. 98, no.
1, pp. 24–30, 2005.
[21] A. D. Santin, S. Bellone, M. Gokden et al., “Overexpression of
HER-2/neu in uterine serous papillary cancer,” Clinical Cancer
Research, vol. 8, no. 5, pp. 1271–1279, 2002.
[22] S. A. Thalberg, “New gynecologic cancer staging,” Obstetrics
and Gynecology, vol. 76, no. 1, p. 158, 1990.
[23] C. Morrison, V. Zanagnolo, N. Ramirez et al., “HER-2 is
an independent prognostic factor in endometrial cancer:
association with outcome in a large cohort of surgically staged
patients,” Journal of Clinical Oncology, vol. 24, no. 15, pp.
2376–2385, 2006.
[24] B. Saﬀari, L. A. Jones, A. El-Naggar, J. C. Felix, J. George, and
M. F. Press, “Ampliﬁcation and overexpression of HER-2/neu
(c-erbB2) in endometrial cancers: correlation with overall
survival,” Cancer Research, vol. 55, no. 23, pp. 5693–5698,
1995.
[25] Y. L. Ren, H. Y. Wang, L. Shen, and W. T. Yang, “Clinical
and pathologic analysis of 33 cases of uterine papillary serous
carcinoma,” Zhonghua Fu Chan Ke Za Zhi, vol. 41, no. 12, pp.
817–821, 2006.
[26] A. D. Santin, S. Bellone, E. R. Siegel et al., “Racial diﬀerences
in the overexpression of epidermal growth factor type II
receptor (HER2/neu): a major prognostic indicator in uterine
serous papillary cancer,” American Journal of Obstetrics and
Gynecology, vol. 192, no. 3, pp. 813–818, 2005.
[27] M. M. Zhang, M. K. Cheung, K. Osann et al., “Improved
survival of Asians with corpus cancer compared with whites:
an analysis of underlying factors,” Obstetrics and Gynecology,
vol. 107, no. 2 I, pp. 329–335, 2006.
[28] T. A. Grushko, V. L. Filiaci, A. J. Mundt, K. Ridderstr˚ ale, O. I.
Olopade, and G. F. Fleming, “An exploratory analysis of HER-
2 ampliﬁcation and overexpression in advanced endometrial
carcinoma: a Gynecologic Oncology Group Study,” Gyneco-
logic Oncology, vol. 108, no. 1, pp. 3–9, 2008.
[29] R. Halperin, S. Zehavi, L. Habler, E. Hadas, I. Bukovsky,
and D. Schneider, “Comparative immunohistochemical
study of endometrioid and serous papillary carcinoma of
endometrium,” European Journal of Gynaecological Oncology,
vol. 22, no. 2, pp. 122–126, 2001.
[30] T. P. D´ ıaz-Montes, H. Ji, A. E. Smith Sehdev et al., “Clinical
signiﬁcance of Her-2/neu overexpression in uterine serous
carcinoma,” Gynecologic Oncology, vol. 100, no. 1, pp. 139–
144, 2006.
[ 3 1 ]J .P r a t ,E .O l i v a ,E .L e r m a ,M .V a q u e r o ,a n dX .M a t i a s - G u i u ,
“Uterine papillary serous adenocarcinoma: a 10-case study of
p53 and c-erbB-2 expression and DNA content,” Cancer, vol.
74, no. 6, pp. 1778–1783, 1994.
[32] A. D. Santin, S. Bellone, S. Van Stedum et al., “Ampliﬁcation
of c-erbB2 oncogene: a major prognostic indicator in uterine
serous papillary carcinoma,” Cancer, vol. 104, no. 7, pp. 1391–
1397, 2005.
[33] G. F. Fleming, M. A. Sill, J. T. Thigpen et al., “Phase II
evaluation of Trastuzumab in patients with advanced or
recurrent endometrial carcinoma: a report on GOG 181B,”
Journal of Clinical Oncology, vol. 22, p. 453, 2003.
[ 3 4 ]J .A .V i l l e l l a ,S .C o h e n ,D .H .S m i t h ,H .H i b s h o o s h ,a n dD .
Hershman, “HER-2/neu overexpression in uterine papillary
serous cancers and its possible therapeutic implications,”
InternationalJournalofGynecologicalCancer,v ol.16,no .5,pp .
1897–1902, 2006.